JP2005536458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005536458A5 JP2005536458A5 JP2003587786A JP2003587786A JP2005536458A5 JP 2005536458 A5 JP2005536458 A5 JP 2005536458A5 JP 2003587786 A JP2003587786 A JP 2003587786A JP 2003587786 A JP2003587786 A JP 2003587786A JP 2005536458 A5 JP2005536458 A5 JP 2005536458A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- trifluoromethyl
- benzyl
- alkyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 50
- 229910052757 nitrogen Inorganic materials 0.000 claims 26
- -1 cyano, difluoromethyl Chemical group 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- HOBYJILAXVUFGC-UHFFFAOYSA-N 1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-morpholin-4-yltriazole-4-carboxylic acid Chemical compound C1COCCN1C1=C(C(=O)O)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HOBYJILAXVUFGC-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- DYUZKVKGQMWOHS-UHFFFAOYSA-N 5-(1-benzyltriazol-4-yl)-1-phenyltetrazole Chemical compound C1=C(C=2N(N=NN=2)C=2C=CC=CC=2)N=NN1CC1=CC=CC=C1 DYUZKVKGQMWOHS-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- JJPIGEXCMDBEMH-UHFFFAOYSA-N [1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-phenyltriazol-4-yl]-[5-(2-chlorophenyl)-3-(1,3-dioxolan-2-ylmethyl)-1,2-oxazol-4-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(C(=O)C3=C(ON=C3CC3OCCO3)C=3C(=CC=CC=3)Cl)N=N2)C=2C=CC=CC=2)=C1 JJPIGEXCMDBEMH-UHFFFAOYSA-N 0.000 claims 1
- UXRDGMJODWUWEQ-UHFFFAOYSA-N [1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-phenyltriazol-4-yl]-[5-(2-chlorophenyl)-3-(2,2-dimethoxyethyl)-1,2-oxazol-4-yl]methanone Chemical compound COC(OC)CC1=NOC(C=2C(=CC=CC=2)Cl)=C1C(=O)C(=C1C=2C=CC=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UXRDGMJODWUWEQ-UHFFFAOYSA-N 0.000 claims 1
- XJNBGUMELPUFLS-UHFFFAOYSA-N [1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-phenyltriazol-4-yl]-[5-(2-chlorophenyl)-3-(oxan-2-yloxymethyl)-1,2-oxazol-4-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(C(=O)C3=C(ON=C3COC3OCCCC3)C=3C(=CC=CC=3)Cl)N=N2)C=2C=CC=CC=2)=C1 XJNBGUMELPUFLS-UHFFFAOYSA-N 0.000 claims 1
- LANMBYGFTCFMTE-UHFFFAOYSA-N [1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyrazin-2-yltriazol-4-yl]-[5-(2-chlorophenyl)-3-(oxan-2-yloxymethyl)-1,2-oxazol-4-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(C(=O)C3=C(ON=C3COC3OCCCC3)C=3C(=CC=CC=3)Cl)N=N2)C=2N=CC=NC=2)=C1 LANMBYGFTCFMTE-UHFFFAOYSA-N 0.000 claims 1
- WDWKUSVIIQGHQR-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyrazin-2-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2N=CC=NC=2)=C1 WDWKUSVIIQGHQR-UHFFFAOYSA-N 0.000 claims 1
- BXFJVJCTOXNGQB-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-3-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=NC=CC=2)=C1 BXFJVJCTOXNGQB-UHFFFAOYSA-N 0.000 claims 1
- JIJJAZDLZXELGY-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanol Chemical compound C=1C=CN=C(C2=C(N(CC=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)N=N2)C=2C=CN=CC=2)C=1C(O)C1=CC=CC=C1Cl JIJJAZDLZXELGY-UHFFFAOYSA-N 0.000 claims 1
- WQEHSGBEFASOHS-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)C1=CC=CN=C1C1=C(C=2C=CN=CC=2)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N=N1 WQEHSGBEFASOHS-UHFFFAOYSA-N 0.000 claims 1
- TUUOIQSGBHLSKF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)C(F)(F)F)C=2C=CN=CC=2)=C1 TUUOIQSGBHLSKF-UHFFFAOYSA-N 0.000 claims 1
- DKHLRIALSSMNMH-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-phenylmethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C=CC=CC=2)C=2C=CN=CC=2)=C1 DKHLRIALSSMNMH-UHFFFAOYSA-N 0.000 claims 1
- ZOMUMFVDDNPLHR-UHFFFAOYSA-N [3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-3-yltriazol-4-yl]-5-(2-hydroxypropan-2-yl)-1,2-oxazol-4-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C1=C(C(C)(O)C)ON=C1C(=C1C=2C=NC=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZOMUMFVDDNPLHR-UHFFFAOYSA-N 0.000 claims 1
- DVQMEYVCSVHHIR-UHFFFAOYSA-N [3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-3-yltriazol-4-yl]pyridazin-4-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=NN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=NC=CC=2)=C1 DVQMEYVCSVHHIR-UHFFFAOYSA-N 0.000 claims 1
- SJMNZGLLWWUYIN-UHFFFAOYSA-N [3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]-5-(2-hydroxypropan-2-yl)-1,2-oxazol-4-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C1=C(C(C)(O)C)ON=C1C(=C1C=2C=CN=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SJMNZGLLWWUYIN-UHFFFAOYSA-N 0.000 claims 1
- NMHNQKRRUSVPCP-UHFFFAOYSA-N [3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-2-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=NC=CC=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 NMHNQKRRUSVPCP-UHFFFAOYSA-N 0.000 claims 1
- JAXKVNCEOBSTOO-UHFFFAOYSA-N [3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyrimidin-5-yltriazol-4-yl]pyridazin-4-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=NN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=NC=NC=2)=C1 JAXKVNCEOBSTOO-UHFFFAOYSA-N 0.000 claims 1
- NDYYFTKAIFQOJM-UHFFFAOYSA-N [4-amino-2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-morpholin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C=1C(N)=CC=NC=1C(=C1N2CCOCC2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NDYYFTKAIFQOJM-UHFFFAOYSA-N 0.000 claims 1
- IEOKPAZUAWVYSZ-UHFFFAOYSA-N [4-amino-2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C=1C(N)=CC=NC=1C(=C1C=2C=CN=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IEOKPAZUAWVYSZ-UHFFFAOYSA-N 0.000 claims 1
- CGQHWJPXQWVUQD-UHFFFAOYSA-N [5-amino-3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridazin-4-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C=1C(N)=CN=NC=1C(=C1C=2C=CN=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CGQHWJPXQWVUQD-UHFFFAOYSA-N 0.000 claims 1
- ICNFGDHPGXLYIV-UHFFFAOYSA-N [5-amino-3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyrimidin-5-yltriazol-4-yl]pyridazin-4-yl]-(2-chlorophenyl)methanone Chemical compound C=1C=CC=C(Cl)C=1C(=O)C=1C(N)=CN=NC=1C(=C1C=2C=NC=NC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ICNFGDHPGXLYIV-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- VIIBBPXKXFDNCM-UHFFFAOYSA-N n-(2-aminoethyl)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[(2-chlorophenyl)methyl]-5-pyridin-4-yltriazole-4-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=NN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(C=2C=CN=CC=2)=C1C(=O)N(CCN)CC1=CC=CC=C1Cl VIIBBPXKXFDNCM-UHFFFAOYSA-N 0.000 claims 1
- OKJJLWPTGGAJPP-UHFFFAOYSA-N n-(2-aminoethyl)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[1-(2-chlorophenyl)ethyl]-5-morpholin-4-yltriazole-4-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=C(Cl)C=1C(C)N(CCN)C(=O)C(=C1N2CCOCC2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OKJJLWPTGGAJPP-UHFFFAOYSA-N 0.000 claims 1
- HEXDAWONLKSDID-UHFFFAOYSA-N n-(2-aminoethyl)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[1-(2-chlorophenyl)ethyl]-5-pyridin-4-yltriazole-4-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=C(Cl)C=1C(C)N(CCN)C(=O)C(=C1C=2C=CN=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HEXDAWONLKSDID-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims 1
- SNPMEGSZVSNMOZ-UHFFFAOYSA-N tert-butyl n-[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-chlorotriazole-4-carbonyl]-[(2-chlorophenyl)methyl]amino]ethyl]carbamate Chemical compound N1=NN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(Cl)=C1C(=O)N(CCNC(=O)OC(C)(C)C)CC1=CC=CC=C1Cl SNPMEGSZVSNMOZ-UHFFFAOYSA-N 0.000 claims 1
- WKKKABSVGHXWPZ-UHFFFAOYSA-N tert-butyl n-[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-chlorotriazole-4-carbonyl]-[1-(2-chlorophenyl)ethyl]amino]ethyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C(C)N(CCNC(=O)OC(C)(C)C)C(=O)C(=C1Cl)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WKKKABSVGHXWPZ-UHFFFAOYSA-N 0.000 claims 1
- RCRKCUFVQRCCSF-UHFFFAOYSA-N tert-butyl n-[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-morpholin-4-yltriazole-4-carbonyl]-[1-(2-chlorophenyl)ethyl]amino]ethyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C(C)N(CCNC(=O)OC(C)(C)C)C(=O)C(=C1N2CCOCC2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RCRKCUFVQRCCSF-UHFFFAOYSA-N 0.000 claims 1
- ZFMMLUSURHYMIT-UHFFFAOYSA-N tert-butyl n-[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazole-4-carbonyl]-[(2-chlorophenyl)methyl]amino]ethyl]carbamate Chemical compound N1=NN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(C=2C=CN=CC=2)=C1C(=O)N(CCNC(=O)OC(C)(C)C)CC1=CC=CC=C1Cl ZFMMLUSURHYMIT-UHFFFAOYSA-N 0.000 claims 1
- HPHXLNXAEKWJPY-UHFFFAOYSA-N tert-butyl n-[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazole-4-carbonyl]-[1-(2-chlorophenyl)ethyl]amino]ethyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C(C)N(CCNC(=O)OC(C)(C)C)C(=O)C(=C1C=2C=CN=CC=2)N=NN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HPHXLNXAEKWJPY-UHFFFAOYSA-N 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37612102P | 2002-04-26 | 2002-04-26 | |
| PCT/US2003/010681 WO2003091226A1 (en) | 2002-04-26 | 2003-04-22 | Triazole derivatives as tachykinin receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005536458A JP2005536458A (ja) | 2005-12-02 |
| JP2005536458A5 true JP2005536458A5 (OSRAM) | 2006-06-15 |
| JP4559087B2 JP4559087B2 (ja) | 2010-10-06 |
Family
ID=29270766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587786A Expired - Lifetime JP4559087B2 (ja) | 2002-04-26 | 2003-04-22 | タキキニン受容体アンタゴニストとしてのトリアゾール誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7320994B2 (OSRAM) |
| EP (1) | EP1501809B1 (OSRAM) |
| JP (1) | JP4559087B2 (OSRAM) |
| KR (1) | KR100755577B1 (OSRAM) |
| CN (1) | CN1312136C (OSRAM) |
| AR (1) | AR039329A1 (OSRAM) |
| AT (1) | ATE384053T1 (OSRAM) |
| AU (1) | AU2003230829B8 (OSRAM) |
| BR (1) | BRPI0309534B8 (OSRAM) |
| CA (1) | CA2483159C (OSRAM) |
| CR (1) | CR7548A (OSRAM) |
| CY (1) | CY1107221T1 (OSRAM) |
| DE (1) | DE60318697T2 (OSRAM) |
| DK (1) | DK1501809T3 (OSRAM) |
| EA (1) | EA007720B1 (OSRAM) |
| EC (1) | ECSP045391A (OSRAM) |
| ES (1) | ES2298513T3 (OSRAM) |
| HR (1) | HRP20041008B1 (OSRAM) |
| IL (2) | IL164675A0 (OSRAM) |
| MX (1) | MXPA04010622A (OSRAM) |
| MY (1) | MY141559A (OSRAM) |
| NO (1) | NO333647B1 (OSRAM) |
| NZ (1) | NZ535886A (OSRAM) |
| PE (1) | PE20040600A1 (OSRAM) |
| PL (1) | PL212090B1 (OSRAM) |
| PT (1) | PT1501809E (OSRAM) |
| TW (1) | TWI265807B (OSRAM) |
| UA (1) | UA79113C2 (OSRAM) |
| WO (1) | WO2003091226A1 (OSRAM) |
| ZA (1) | ZA200408670B (OSRAM) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2005000821A1 (en) * | 2003-06-12 | 2005-01-06 | Eli Lilly And Company | Tachykinin receptor antagonists |
| JP4959336B2 (ja) * | 2003-10-24 | 2012-06-20 | イーライ リリー アンド カンパニー | ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態 |
| EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
| US8952176B2 (en) * | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| WO2007012579A1 (en) * | 2005-07-25 | 2007-02-01 | F. Hoffmann-La Roche Ag | Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| AU2006347397A1 (en) * | 2006-08-18 | 2008-02-21 | Syngenta Limited | Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| EP2065377B1 (en) | 2006-09-21 | 2011-11-23 | Eisai R&D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| BRPI0721069A2 (pt) | 2006-12-20 | 2014-02-04 | Lilly Co Eli | Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona |
| US8110588B2 (en) | 2007-08-08 | 2012-02-07 | Neurosearch A/S | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| GB0823002D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isoxazoles derivatives with plant growth regulating properties |
| US9782397B2 (en) | 2011-07-04 | 2017-10-10 | Irbm Science Park S.P.A. | Treatment of corneal neovascularization |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| PT3265087T (pt) | 2015-03-04 | 2020-10-15 | Vanda Pharmaceuticals Inc | Método de tratamento com tradipitant |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| JP6884801B2 (ja) | 2016-05-31 | 2021-06-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| CN111093671A (zh) | 2017-09-13 | 2020-05-01 | 万达制药公司 | 以托吡坦对特应性皮炎的改进治疗 |
| SI3710000T1 (sl) | 2017-11-17 | 2025-07-31 | Vanda Pharmaceuticals Inc. | Tradipitant za uporabo pri zdravljenju gastropareze |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| EP3801514A1 (en) | 2018-06-08 | 2021-04-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| HRP20250097T1 (hr) * | 2018-09-28 | 2025-03-28 | Vanda Pharmaceuticals Inc. | Primjena tradipitanta kod bolesti kretanja |
| EP3890735A1 (en) | 2018-12-03 | 2021-10-13 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| IL295327A (en) | 2020-02-25 | 2022-10-01 | Vanda Pharmaceuticals Inc | Improved treatment of atopic dermatitis with tradipitant |
| EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
| US20230145932A1 (en) | 2020-03-26 | 2023-05-11 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| KR20220165251A (ko) | 2020-04-03 | 2022-12-14 | 네르 쎄라퓨틱스 리미티드 | 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제 |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| IL298589A (en) | 2020-06-02 | 2023-01-01 | Nerre Therapeutics Ltd | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
| CN111662235B (zh) * | 2020-06-23 | 2023-12-22 | 黄淮学院 | 一种苯甲酰基哒嗪衍生物及其制备方法 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| EP4637766A1 (en) | 2022-12-21 | 2025-10-29 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| CN116082253B (zh) * | 2023-02-25 | 2025-04-25 | 浙大城市学院 | 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法 |
| WO2024223617A1 (en) * | 2023-04-24 | 2024-10-31 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| WO1995011880A1 (en) * | 1993-10-27 | 1995-05-04 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| WO1997040025A1 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
| WO1999007677A1 (en) | 1997-08-06 | 1999-02-18 | Eli Lilly And Company | 2-acylaminopropanamines as tachykinin receptor antagonists |
| KR20020067548A (ko) * | 1999-12-17 | 2002-08-22 | 쉐링 코포레이션 | 선택적인 뉴로키닌 길항제 |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
| JP2002123925A (ja) | 2000-10-13 | 2002-04-26 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
| CN1313450C (zh) * | 2002-04-26 | 2007-05-02 | 伊莱利利公司 | 速激肽受体拮抗剂 |
-
2003
- 2003-04-22 AT AT03723929T patent/ATE384053T1/de active
- 2003-04-22 BR BRPI0309534A patent/BRPI0309534B8/pt not_active IP Right Cessation
- 2003-04-22 CA CA2483159A patent/CA2483159C/en not_active Expired - Lifetime
- 2003-04-22 MX MXPA04010622A patent/MXPA04010622A/es active IP Right Grant
- 2003-04-22 DE DE60318697T patent/DE60318697T2/de not_active Expired - Lifetime
- 2003-04-22 JP JP2003587786A patent/JP4559087B2/ja not_active Expired - Lifetime
- 2003-04-22 TW TW092109375A patent/TWI265807B/zh not_active IP Right Cessation
- 2003-04-22 WO PCT/US2003/010681 patent/WO2003091226A1/en not_active Ceased
- 2003-04-22 PT PT03723929T patent/PT1501809E/pt unknown
- 2003-04-22 NZ NZ535886A patent/NZ535886A/en not_active IP Right Cessation
- 2003-04-22 KR KR1020047017206A patent/KR100755577B1/ko not_active Expired - Lifetime
- 2003-04-22 DK DK03723929T patent/DK1501809T3/da active
- 2003-04-22 ES ES03723929T patent/ES2298513T3/es not_active Expired - Lifetime
- 2003-04-22 PE PE2003000400A patent/PE20040600A1/es not_active Application Discontinuation
- 2003-04-22 MY MYPI20031515A patent/MY141559A/en unknown
- 2003-04-22 US US10/512,249 patent/US7320994B2/en not_active Expired - Lifetime
- 2003-04-22 CN CNB038091046A patent/CN1312136C/zh not_active Expired - Lifetime
- 2003-04-22 AR ARP030101377A patent/AR039329A1/es unknown
- 2003-04-22 HR HRP20041008AA patent/HRP20041008B1/hr not_active IP Right Cessation
- 2003-04-22 PL PL373504A patent/PL212090B1/pl unknown
- 2003-04-22 UA UA20041008646A patent/UA79113C2/uk unknown
- 2003-04-22 EA EA200401431A patent/EA007720B1/ru not_active IP Right Cessation
- 2003-04-22 AU AU2003230829A patent/AU2003230829B8/en not_active Expired
- 2003-04-22 EP EP03723929A patent/EP1501809B1/en not_active Expired - Lifetime
-
2004
- 2004-10-18 IL IL16467504A patent/IL164675A0/xx not_active IP Right Cessation
- 2004-10-25 CR CR7548A patent/CR7548A/es unknown
- 2004-10-26 EC EC2004005391A patent/ECSP045391A/es unknown
- 2004-10-26 ZA ZA200408670A patent/ZA200408670B/xx unknown
- 2004-11-24 NO NO20045120A patent/NO333647B1/no not_active IP Right Cessation
-
2008
- 2008-02-28 CY CY20081100235T patent/CY1107221T1/el unknown
-
2009
- 2009-04-07 IL IL198122A patent/IL198122A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005536458A5 (OSRAM) | ||
| CA2483159A1 (en) | Triazole derivatives as tachykinin receptor antagonists | |
| AU2011287574B2 (en) | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | |
| RU2506267C2 (ru) | Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение | |
| JP2008044952A (ja) | 高コンダクタンス型カルシウム感受性ｋチャネル開口薬 | |
| JP2006500348A5 (OSRAM) | ||
| RU2007138978A (ru) | Гетероциклическое соединение | |
| RU2005116689A (ru) | Средство для профилактики или лечения невропатии | |
| WO2001068585A1 (en) | Novel amide compounds | |
| RU2006127575A (ru) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| JP2008516974A5 (OSRAM) | ||
| AU2011238616A1 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
| JP2011517457A5 (OSRAM) | ||
| HRP20170029T1 (hr) | Derivati triazola ili njihove soli | |
| RU2006125446A (ru) | Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение | |
| CA2484188A1 (en) | Tachykinin receptor antagonists | |
| RU2015122698A (ru) | Производное пиридина | |
| RU2009111113A (ru) | Мидуляторы mglur5 | |
| JP2006501273A5 (OSRAM) | ||
| AU714701B2 (en) | Novel thiophene derivative and pharmaceutical composition thereof | |
| CA3189738A1 (en) | Novel oxadiazole-based selective hdac6 inhibitors | |
| FR2903405A1 (fr) | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications | |
| CA2539297A1 (en) | Substituted triazole derivatives as oxytocin antagonists | |
| CN102666500B (zh) | 7元环化合物及其药物用途 | |
| JPH11240832A5 (OSRAM) |